Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Expected currency impact for full year 2021 and 2022 5 1 Currency impact vs. PY %pts, assuming late-October exchange rates prevail in 2021 and 2022 0 3 FX impact on Net sales FX impact on Core operating income I I I I I 5 3 2 I 1 2 I I I I I I -1 -1 0 to -1 I -1 to -2 I I FY Q1 -4 I I I I I Q2 Q3 Q4 FY¦ FY FY Q1 Q2 Q3 Q4 FY ¦ FY I I 2020 ¦ I I I I I I 2021 I 2022 2020 2021 2022 Actual Simulation 43 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation